Perampanel as first add-on antiseizure medication: Italian consensus clinical practice statements
Abstract Background When use of a single antiseizure medication (ASM) fails to induce seizure remission, add-on therapy is justified. Perampanel (PER) is approved in Europe as adjunctive therapy for focal, focal to bilateral tonic-clonic seizures and generalized tonic-clonic seizures. Aim of the stu...
Main Authors: | Paolo Bonanni, Antonio Gambardella, Paolo Tinuper, Benedetto Acone, Emilio Perucca, Giangennaro Coppola |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-10-01
|
Series: | BMC Neurology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12883-021-02450-y |
Similar Items
-
Correction: Perampanel as first add-on antiseizure medication: Italian consensus clinical practice statements
by: Paolo Bonanni, et al.
Published: (2022-05-01) -
Current role of perampanel in pediatric epilepsy
by: Paola De Liso, et al.
Published: (2017-06-01) -
Perampanel: New drug for treatment of refractory partial onset seizures
by: Santosh Kumar Singh, et al.
Published: (2014-01-01) -
Successful Treatment of Primary Orthostatic Tremor Using Perampanel
by: Anant Wadhwa, et al.
Published: (2019-08-01) -
Simple and rapid validated HPLC-fluorescence determination of perampanel in the plasma of patients with epilepsy
by: Susan Mohamed, et al.
Published: (2018-03-01)